Please login to the form below

Not currently logged in
Email:
Password:

eIF4E inhibitor

This page shows the latest eIF4E inhibitor news and features for those working in and with pharma, biotech and healthcare.

Pfizer signs $507m cancer deal with Effector Therapeutics

Pfizer signs $507m cancer deal with Effector Therapeutics

Despite being highly oncogenic target which has garnered significant interest from the pharma industry, eIF4E has remained an evasive target for researchers. ... Importantly, we believe that this agreement validates Effector’s pursuit of eIF4E, which

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Frontera Group

A leading global patient-activation group - comprising of a digital insight consultancy, creative activation agency. Our foundations lie in behavioural...

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Infographics